Compare OMH & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | VRAX |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | Singapore | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 1.7M |
| IPO Year | 2022 | 2021 |
| Metric | OMH | VRAX |
|---|---|---|
| Price | $1.34 | $0.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 23.7K | ★ 185.2K |
| Earning Date | 11-28-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | $217,274.83 |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.18 |
| 52 Week High | $4.33 | $1.35 |
| Indicator | OMH | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 54.25 | 38.72 |
| Support Level | $1.03 | N/A |
| Resistance Level | $1.37 | $0.25 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 79.49 | 13.89 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.